Table 3 Results of ELISA using PM1-α peptide with polymyositis/scleroderma and various control sera
From: Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen
Number (%) of anti-PM1-α-positive sera | Mean value/standard deviation | Top value | |
|---|---|---|---|
Polymyositis/scleroderma (n = 40) | 22 (55) | 3.1/3.2 | 11.6 |
Rheumatic disease controls (n = 452) | 33 (7.3) | 0.6/0.9 | 7.7 |
Polymyositis (n = 40) | 3 (7.5) | 1.0/1.1 | 7.4 |
Scleroderma (n = 205) | 27 (13.2) | 0.9/1.2 | 7.5 |
Rheumatoid arthritis (n = 69) | 0 (0) | 0.3/0.2 | 1.1 |
Mixed connective tissue disease (n = 6) | 0 (0) | 0.4/0.1 | 0.6 |
Undifferentiated connective tissue disease (n = 10) | 0 (0) | 0.3/0.0 | 0.4 |
Systemic lupus erythematosus (n = 114) | 3 (2.6) | 0.5/0.7 | 7.7 |
Other rheumatic diseases (n = 8) | 0 (0) | 0.3/0.1 | 0.6 |
Hepatitis C virus (n = 48) | 2 (4.2) | 0.5/0.5 | 2.6 |
Organ specific disorders (n = 23) | 0 (0) | 0.4/0.2 | 0.8 |
Hashimoto thyroiditis (n = 11) | 0 (0) | 0.3/0.2 | 0.8 |
Grave's disease (n = 12) | 0 (0) | 0.4/0.2 | 0.8 |
Healthy individuals (n = 4) | 0 (0) | 0.6/0.2 | 0.7 |